

### Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (PNHS) (WP4), with a focus on the period from July to September 2020.

During the summer of 2020, some sites were able to re-open and resume activities at different levels, considering the ongoing COVID-19 pandemic across European countries. By the end of September 2020, most sites had (partially or fully) re-opened and resumed some activities, including recruitment (only at sites enrolling participants from non-EPAD LCS Parent Cohorts).

In September 2020, most sites submitted the global protocol amendment to Ethics Committees and Regulatory Authorities, which is expected to be approved in (the beginning of) Q4 2020. This approval will allow sites to resume recruitment of former EPAD LCS participants, which is expected to have a positive impact on the overall study progress.

The gradual re-opening of sites after lockdown due to COVID-19 crisis and the delay in enrolment from EPAD LCS participants due to the need for a global protocol amendment have resulted in a sustained slow recruitment of participants during Q3 2020. Although it is expected that the approval of the global protocol amendment will have a positive impact on recruitment, the continued local measures to contain COVID-19 and a possible second wave in European countries can also have a negative impact, at least until the end of 2020. Considering this uncertain context, two recruitment projections have been proposed, both of which demonstrate the direct impact of COVID-19 and an early EPAD LCS closure to the final numbers in AMYPAD PNHS, which are likely to fall short of the original target of 2000 participants enrolled.

In conclusion, the last quarter has seen slow progress in AMYPAD PNHS recruitment due to the continued effect of COVID-19 crisis and the gradual re-opening of sites, with 647 participants consented of which 466 have already undergone PET scanning. Moving forward, the Q4 of 2020 should see the approval of the global amendment across all sites, and it is expected that all sites will resume recruitment, likely at reduced capacity depending on COVID-19 measures. Therefore, the final quarter of the year might show an increase in recruitment of participants (particularly for EPAD LCS and new PCs) and PET scans performed.

**For more information:** [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative  
medicines  
initiative